News & Media News & Media

17 November 2022
Abionic Webinar – Guiding Clinical Care Using Pancreatic Stone Protein

Abionic Webinar – Guiding Clinical Care Using Pancreatic Stone Protein


Another successful webinar was held by Abionic SA on September 22nd, 2022. More than 240 attendees from all over the world had the opportunity to connect and tune into this educational session where it was highlighted the role of Point-Of-Care (POC) testing in the early identification and management of sepsis and moreover, how the use of Pancreatic Stone Protein (PSP) can guide clinical care. 


The webinar along with interactive roundtable discussions, chaired and moderated by Prof. Jean-Louis Vincent, world-renowned expert in sepsis and professor of intensive care at the Erasme University Hospital in Brussels, Belgium, was joined by three expert physicians; Dr. Holger Klein (Kantonsspital, Switzerland), Dr. Gabriele Melegari (Ospedale di Baggiovara, Italy) and Prof. Dr. Maria Lagadinou, Assistant Professor of Internal Medicine at the University Hospital of Patras in Greece.


Opening the session, Prof. Vincent mentioned that there is a “need for better biomarkers to identify sepsis, assess its severity and [..] which we can follow over time to individualize the duration of antibiotic therapy and ensure we are in the right direction with our current management.”


From his side, Dr. Klein highlighted that "PSP is an upcoming promising biomarker for sepsis […] as it steeply increases before clinically proven sepsis and shows high level of robustness towards sterile inflammatory stimuli such as trauma itself or repetitive surgeries” and “that its use on the abioSCOPE® enables Point-of-Care diagnostics for our physicians in the ICU and even also in the emergency department” while Dr. Melegari underlined the need for “an ideal biomarker which should have high accuracy, predictive value, high sensitivity and specificity and be easy to perform”.


Dr. Lagadinou shared her own experience using PSP in the management of critically ill COVID-19 patients. In a study that was conducted at the University Hospital of Patras with the aim to evaluate the prognostic value of PSP in hospitalized patients with COVID-19, results demonstrated that “PSP measured on admission, could be used for identification of patients with SARS-CoV-2 pneumonia at highest risk of prolonged hospitalization reflecting more severe disease and the need for intensive treatment”, suggesting that “maybe we will be able to create a triage based on an easily measured biomarker […] to manage resources and apply earlier proper treatment”.


Watch the full webinar here.